Our advice for clinicians on the coronavirus is here.
If you are a member of the public looking for health advice, go to the NHS website. And if you are looking for the latest travel information, and advice about the government response to the outbreak, go to the GOV.UK website.
A patient safety alert has been issued today (14 April 2014) by NHS England on residual anaesthetic drugs in cannulae and intravenous lines leading to cardiac or respiratory arrest.
The alert has been issued to all NHS services hospitals and community services in England that undertake surgery or other investigations and procedures using anaesthesia.
Since January 2011 there have been six incidents of cardiac or respiratory arrest due to residual anaesthetic drugs in cannulae reported to the national reporting and learning system (NRLS). After intravenous anaesthesia, some drug may be left in the cannula, or in the intravenous line distal to a site of drug injection, which is then flushed into the patient’s circulation when further fluid or medication is given through the same cannula or line. This may also happen when ward staff give antibiotics or pain relief after the patient returns from theatre.
From the incidents reported it appears that systems were not in place to ensure that all cannulae and extensions were flushed with saline or another solution that does not contain anaesthetic drugs before the patient left recovery or the department where the procedure/investigation was undertaken.
Dr Mike Durkin, National Director of Patient Safety, NHS England, said: “This is now the eighth alert we have issued using NHS England’s National Patient Safety Alerting System, which was launched in January. Patient safety alerts can cover all aspects of healthcare and are a crucial part of our work to rapidly alert NHS providers to risks and provide guidance on preventing potential incidents that may lead to harm or death. Incidents are identified using our reporting system to spot emerging patterns at a national level, so that appropriate guidance can be developed and issued to protect patients from harm.”